|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Performances | Patients from | | |
| VGCV dosage | Caldés et al.  model (*n* = 98) | Chen et al.  model (*n* = 98) |
|  |  |  |  |
| 900 mg/24h | Relative MPE, (%) | - 16.9 | -13.8 |
| Relative RMSE, (%) | 19.3 | 24.0 |
| Number of MPE of the ±20% interval | 31 (31.6 %) | 31 (31.6 %) |
|  |  |  | |
| 450 mg/24h | Relative MPE, (%) | -14.1 | -16.8 |
| Relative RMSE, (%) | 17.4 | 32.7 |
| Number of MPE of the ±20% interval | 23 (23.5 %) | 37 (37.8 %) |
|  |  |  | |
| 450 mg/48h | Relative MPE, (%) | -25.7 | 0.05 |
| Relative RMSE, (%) | 27.7 | 37.5 |
| Number of MPE of the ±20% interval | 69 (70.4 %) | 71 (72.4 %) |
|  |  |  | |
| 450 mg/72h | Relative MPE, (%) | -28.4 | - |
| Relative RMSE, (%) | 31.1 | - |
| Number of MPE of the ±20% interval | 73 (74.5 %) | - |